Loading
Bioventus Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Aug 2024.
Bioventus Inc.: what insiders have been doing
Bioventus Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Bioventus Inc. logged 29 filings by 14 insiders.
All open-market trades in the period are sales: 3 sales worth €269k, by 2 insiders, with no purchase on record. Biggest ticket of the year: €114k, sold by McMurry-Heath Michelle and made public on 10 November 2025.
Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 29 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 16 purchases against 33 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 568.1 m USD and net income of 22.7 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
171
Thresholds
n/a
Buy Volume
€6M
16 ops. · all time
Sell Volume
€1M
33 ops. · all time
Who traded when
BuySaleAnthony D'Adamio4 sales
Katrina J. Church4 sales
Mark Leonard Singleton4 sales
Michelle McMurry-Heath2 sales
Guy P. Nohra1 sale
Robert E. Claypoole1 sale
Since the insiders bought
- -22.4%Entry US$9.12 · Close at T+365 US$7.08
- +150.1%Entry US$3.95 · Close at T+365 US$9.88
- +76.9%Entry US$4.68 · Close at T+365 US$8.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,029 of 24,148 companies
59.9
score / 100
Value55
Quality65
FCF yld7.5%
Earn yld2.4%
EV/EBITDA12.6x
ROE26%
Gross mgn68%
Net mgn4.0%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.00
Analyst consensus
5 analysts1.40/5
US$15.00Target US$17.60(+26%)US$19.00
Income statement
RevenueUS$568.1M
Gross profitUS$388.2M68% margin
EBITDAUS$99.2M17% margin
Net incomeUS$22.7M9.4% margin
Valuation
PER (trailing)17.9x
PER (forward)15.2x
P/Book4.2x
Beta0.65
Balance sheet & cash
Market capUS$956.3M
Total debtUS$294M
Free Cash FlowUS$72.1M
Debt / Equity95%
Profitability & ownership
ROE25.7%
ROA5.5%
% insiders11.7%
% institutions83.4%
Last declaration on 4 June 2026
Declarations171 total
39,789 shares0Class A Common StockSEC:0001106508-26-000003:0
32,282 shares0Class A Common StockSEC:0001198330-26-000002:0
32,282 shares0Class A Common StockSEC:0001221375-26-000002:0
32,282 shares0Class A Common StockSEC:0001222362-26-000008:0
32,282 shares0Class A Common StockSEC:0001760737-26-000004:0
32,282 shares0Class A Common StockSEC:0001382909-26-000001:0
32,282 shares0Class A Common StockSEC:0001017832-26-000002:0
32,282 shares0Class A Common StockSEC:0001679773-26-000006:0
32,282 shares0Class A Common StockSEC:0001904156-26-000004:0
4,312 shares@ US$9.060.0033% mcap11.1% of flowClass A Common StockSEC:0001835184-26-000007:1
5,648 shares@ US$9.060.0044% mcap10.0% of flowClass A Common StockSEC:0001914936-26-000009:1
1,868 shares@ US$9.060.0014% mcap9.9% of flowClass A Common StockSEC:0001204391-26-000006:1
4,300 shares0Class A Common StockSEC:0001204391-26-000006:0
9,925 shares0Class A Common StockSEC:0001835184-26-000007:0
13,000 shares0Class A Common StockSEC:0001914936-26-000009:0
18,625 shares0Class A Common StockSEC:0001914936-26-000007:0
33,500 shares0Class A Common StockSEC:0002005474-26-000004:0
13,500 shares0Class A Common StockSEC:0001914936-26-000004:0
8,886 shares0Class A Common StockSEC:0001835184-26-000005:0
3,455 shares0Class A Common StockSEC:0001204391-26-000004:0
12,000 shares@ US$8.786644.4% of flowClass A Common StockSEC:0001904156-26-000002:0
4,375 shares0Class A Common StockSEC:0001204391-26-000002:0
20,153 shares0Class A Common StockSEC:0001914936-26-000002:0
12,980 shares0Class A Common StockSEC:0001835184-26-000003:0
25 of 171 declarations
About Bioventus Inc.
Bioventus Inc. (ticker: BVS) is a U.S.-based medical-device company listed on the Nasdaq in the United States. The company is focused on “active healing” solutions designed to improve patient recovery and mobility through clinically differentiated, minimally invasive treatments. Founded in 2012 in North Carolina, Bioventus is headquartered in Durham, North Carolina, and maintains a broader operating footprint across the United States, Canada, and the Netherlands. That combination of domestic roots and international commercial reach gives the group an established platform in specialized orthopedic and pain-management markets.
Bioventus’ business is organized around three core areas. Pain Treatments includes DUROLANE, GELSYN-3, and SUPARTZ FX, which are hyaluronic acid therapies used for knee osteoarthritis, as well as StimRouter, a peripheral nerve stimulation system for chronic peripheral nerve pain. The company also sells XCELL PRP, a platelet-rich plasma processing system. Restorative Therapies is anchored by EXOGEN, an ultrasound bone-healing system intended to stimulate the body’s natural healing process and support fracture recovery. Surgical Solutions covers a portfolio of bone graft substitutes and minimally invasive surgical technologies, including ultrasonic devices for hard- and soft-tissue removal.
Read moreShow less
From a competitive standpoint, Bioventus operates in attractive but crowded niches at the intersection of orthopedics, pain management, and surgical biologics. Its market position is built less on scale than on specialization: a focused portfolio, strong brand recognition in selected procedures, and a strategy that emphasizes non-surgical or less invasive alternatives to traditional treatment pathways. The company also relies on a mix of internal product development, acquisitions, and distribution agreements to broaden its commercial offering. Bioventus states that its products are available in more than 50 countries, underscoring its international reach.
Recent developments have been constructive. In March 2026, Bioventus reported full-year 2025 results showing 7.5% organic revenue growth, improved profitability, and stronger operating cash flow. Management highlighted above-market growth across the portfolio and particularly strong performance in Pain Treatments and Surgical Solutions. In August 2025, the company said FDA clearances for TalisMann and StimTrial created an additional growth driver in chronic peripheral nerve pain. In July 2025, Bioventus announced a new $400 million senior secured credit agreement, which it said would lower interest expense and improve liquidity. For investors, Bioventus looks like a mid-cap healthcare name with a specialized product set, a relatively defensive end-market profile, and ongoing execution around margin expansion, portfolio refinement, and pipeline development.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
